
Prevnar 20 tile presented on page 6 was submitted as part of a subpart E submission under job code PP-PNR-USA-0049

Pfizer logo in Champion Sponsorship area. With this option the User will skip the Association Profile Page and go directly to the Pfizer Unbranded Landing Page.

Site Map



FDA-CBER-2021-5683-0951434

Please reference page 5

for linking information


Association Exhibit Listing - Champion sponsorship within the association platform

Notes: When the user clicks the Pfizer logo, they will be directed directly to Pfizer Landing page. Shown on page 5.




Zoomed Viewed – Association Exhibit Listing - Champion sponsorship within the association platform.

Notes: When the user clicks the Pfizer logo, they will be directed directly to Pfizer Landing page. Shown on page 5.



Pfizer Landing Page



Links to page 6

Key Targets of Covid Virus Lifecycle


URL: www.covidviruslifecycle.com

Microsite

URL: https://www.vr-exhibit.com/MI/113 FDA-CBER-2021-5683-0951437

See page 8

Pfizer Vaccines. When the user selects "Approved and Authorized Vaccines" they will land on this page.



- Links to Page 7
- CLICK HERE Links to: <u>labeling.pfizer.com/showlabeling.aspx?id=501</u>
- Virtual Exhibit https://pfizer.vaccinescongresses.co m/IDWeek2021
- CLICK HERE Links to: <u>labeling.pfizer.com/ShowLabeling.as</u> px?id=1796

Click to learn more – http://www.cvdvaccine-us.com Click HERE Links to USPI:

 $\underline{http://labeling.pfizer.com/ShowLabeling.aspx?id=15623}$

FDA-CBER-2021-5683-0951438

Prevnar 13. When the user selects "Prevnar 13" they will land on this page.



This site is intended for U.S. healthcare professionals.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR PREVNAR 13° FOR ADULTS

IMPORTANT SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13° or any diphtheria toxoid–containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

INDICATION

In adults 18 years of age and older, Prevnar 13* is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

Prevnar 13° will only help protect against
S. pneumoniae serotypes in the vaccine

Please see <u>full Prescribing Information</u> for Prevnar 13.



Select an indication below

Adult Indication

Pediatric Indication

IMPORTANT SAFETY INFORMATION AND INDICATION FOR PREVNAR 13° FOR INFANTS & YOUNG CHILDREN

IMPORTANT SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13° or any diphtheria toxoid–containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
- In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
- In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
- In children 6 years through 17 years of age, Prevnar 13° is administered as a single dose

INDICATIONS

Prevnar 13° is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)



The product information provided in this site is intended only for healthcare professionals in the United States. The products discussed may have different product labeling in other countries.

© 2021 Pfizer Inc. All rights reserved. PP-PNA-USA-4653

Links to the Prevnar 13 Adult HCP site

 Prevnar 13 Adult Website – https://www.pfizerpro.com/product/prevnar-13/adult

Links to the Prevnar 13 Pediatric HCP SIte

 Prevnar 13 Pediatric Website – https://prevnar13pediatric.pfizerpro.com/

Prevnar 13. When the user selects "Prevnar 13" they will land on this page.



This site is intended for U.S. healthcare professionals.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR PREVNAR 13° FOR ADULTS

IMPORTANT SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13° or any diphtheria toxoid–containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

INDICATION

In adults 18 years of age and older, Prevnar 13° is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

Prevnar 13° will only help protect against
S. pneumoniae serotypes in the vaccine

Please see <u>full Prescribing Information</u> for Prevnar 13®.



Select an indication below

Adult Indication

Pediatric Indication

been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks

- In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
- In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
- In children 6 years through 17 years of age, Prevnar 13° is administered as a single dose

INDICATION

Prevnar 13° is a vaccine indicated for active immunization for the prevention of disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)

Limitations of Use and Effectiveness

Prevnar 13° will only help protect against S. pneumoniae serotypes in the vaccine

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for Prevnar 13°.



The product information provided in this site is intended only for healthcare professionals in the United States. The products discussed may have different product labeling in other countries.

© 2021 Pfizer Inc. All rights reserved. PP-PNA-U\$A-4653

Links to http://labeling.pfizer.com/ showlabeling.aspx?id=501

Links to the Prevnar 13 Adult HCP site

 Prevnar 13 Adult Website – https://www.pfizerpro.com/product/prevnar-13/adult

Links to the Prevnar 13 Pediatric HCP SIte

 Prevnar 13 Pediatric Website – https://prevnar13pediatric.pfizerpro.com/ Links to http://labeling.pfizer.com/showlabeling.aspx?id=501